Literature DB >> 3265653

Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells.

G Gallagher1, F Wilcox, F al-Azzawi.   

Abstract

We have examined some of the factors which may regulate the generation and function of human lymphokine-activated killer (LAK) cells. In particular we have studied the effect of cytokines other than interleukin-2 on the ability of human LAK cells to kill human tumour cells. By exposing human tumour cells to human LAK-cells in the presence and absence of interleukin-3 or interleukin-4, we were able to demonstrate that each of these cytokines was able to severely reduce the amount of tumour cell killing. Additionally, we examined the effect of interleukin-3 or interleukin-4 on the production in vitro of human LAK cells by including these materials with interleukin-2 while LAK-cells were being induced. These results showed that not only were these cytokines able to inhibit human LAK-cell function, but they were also able to strongly reduce the ability of interleukin-2 to generate human LAK-cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265653      PMCID: PMC1541800     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  Human antibodies to ovarian cancer antigens secreted by lymphoblastoid cell lines.

Authors:  F Al-Azzawi; W H Stimson; A D Govan
Journal:  J Clin Lab Immunol       Date:  1987-02

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities.

Authors:  F Lee; T Yokota; T Otsuka; P Meyerson; D Villaret; R Coffman; T Mosmann; D Rennick; N Roehm; C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

Review 4.  Adoptive immunotherapy of cancer with activated lymphocytes and interleukin-2.

Authors:  R L Kradin; J T Kurnick
Journal:  Pathol Immunopathol Res       Date:  1986

Review 5.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

Authors:  S A Rosenberg; M T Lotze
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

Review 6.  Immunological regulation of hematopoietic/lymphoid stem cell differentiation by interleukin 3.

Authors:  J N Ihle; Y Weinstein
Journal:  Adv Immunol       Date:  1986       Impact factor: 3.543

7.  Assays detecting the antibody-dependent and independent binding and cytolysis of tumor cells by murine macrophages.

Authors:  W J Johnson; D O Adams
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

8.  Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.

Authors:  A B Tilden; K Itoh; C M Balch
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

9.  Physiology of natural killer cells. In vivo regulation of progenitors by interleukin 3.

Authors:  T Kalland
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

10.  Recombinant interleukin 4 promotes the growth of human T cells.

Authors:  H Spits; H Yssel; Y Takebe; N Arai; T Yokota; F Lee; K Arai; J Banchereau; J E de Vries
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

View more
  8 in total

1.  CD4+ T-helper-cell responses in mice with low-level Candida albicans infection.

Authors:  A Mencacci; R Spaccapelo; G Del Sero; K H Enssle; A Cassone; F Bistoni; L Romani
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

2.  Human lymphokine-activated killer cells develop syngeneic killing ability.

Authors:  G Gallagher; J Findlay; F A al-Azzawi
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

3.  Interleukin-6 enhances the induction of human lymphokine-activated killer cells.

Authors:  G Gallagher; W H Stimson; J Findlay; F al-Azzawi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.

Authors:  B Brooks; H Parry; J Lawry; R Rees
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

5.  Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.

Authors:  B Brooks; K Chapman; J Lawry; A Meager; R C Rees
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

6.  Differential augmentation of in vivo natural killer cytotoxicity in normal primates with recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor.

Authors:  T A Davis; R L Monroy; R R Skelly; R E Donahue; T J MacVittie
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

7.  The putative role of cytokines in the induction of primary anti-phospholipid syndrome in mice.

Authors:  P Fishman; R Bakimer; M Blank; D Sredni; M Djaldetti; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

8.  Cytokines regulate the ability of human LAK-cells to kill human tumour cells in vitro.

Authors:  G Gallagher; F al-Azzawi; J Davis; W H Stimson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.